Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects

PHASE2CompletedINTERVENTIONAL

Enrollment

247

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions

Gastroduodenal Ulceration

Interventions

DRUG

PL2200

PL2200, containing 325 mg aspirin active ingredient

DRUG

Aspirin tablets

325 mg aspirin tablets (USP)

Trial Locations (10)

Jupiter

South Miami

Towson

New York

High Point

Raleigh

Dallas

Houston

San Antonio

Chesapeake